Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer von Moore, Kathleen, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S, Gourley, Charlie, Banerjee, Susana, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William, Mathews, Cara, Liu, Joyce, Lowe, Elizabeth S, Bloomfield, Ralph, DiSilvestro, Paul

Volltext

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial von Oza, Amit M, Prof, Cibula, David, Prof, Benzaquen, Ana Oaknin, MD, Poole, Christopher, Prof, Mathijssen, Ron H J, Prof, Sonke, Gabe S, MD, Colombo, Nicoletta, MD, Špaček, Jiří, MD, Vuylsteke, Peter, MD, Hirte, Holger, MD, Mahner, Sven, MD, Plante, Marie, MD, Schmalfeldt, Barbara, Prof, Mackay, Helen, MD, Rowbottom, Jacqui, PhD, Lowe, Elizabeth S, MD, Dougherty, Brian, PhD, Barrett, J Carl, PhD, Friedlander, Michael, Prof

Volltext

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer von Coleman, Robert L, Fleming, Gini F, Brady, Mark F, Swisher, Elizabeth M, Steffensen, Karina D, Friedlander, Michael, Okamoto, Aikou, Moore, Kathleen N, Efrat Ben-Baruch, Noa, Werner, Theresa L, Cloven, Noelle G, Oaknin, Ana, DiSilvestro, Paul A, Morgan, Mark A, Nam, Joo-Hyun, Leath, Charles A, Nicum, Shibani, Hagemann, Andrea R, Littell, Ramey D, Cella, David, Baron-Hay, Sally, Garcia-Donas, Jesus, Mizuno, Mika, Bell-McGuinn, Katherine, Sullivan, Danielle M, Bach, Bruce A, Bhattacharya, Sudipta, Ratajczak, Christine K, Ansell, Peter J, Dinh, Minh H, Aghajanian, Carol, Bookman, Michael A

Volltext

Endometrial cancer von Makker, Vicky, MacKay, Helen, Ray-Coquard, Isabelle, Levine, Douglas A., Westin, Shannon N., Aoki, Daisuke, Oaknin, Ana

Volltext

Improved Survival with Bevacizumab in Advanced Cervical Cancer von Tewari, Krishnansu S, Sill, Michael W, Long, Harry J, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, Monk, Bradley J

Volltext

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial von Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, López-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J, Boni, Valentina, Calvo, Emiliano, Topalian, Suzanne L, Chen, Tian, Soumaoro, Ibrahima, Li, Bin, Gu, Junchen, Zwirtes, Ricardo, Moore, Kathleen N

Volltext

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial von Swisher, Elizabeth M, Dr Prof, Lin, Kevin K, PhD, Oza, Amit M, Prof, Scott, Clare L, PhD, Giordano, Heidi, MA, Sun, James, PhD, Konecny, Gottfried E, MD, Coleman, Robert L, Prof, Tinker, Anna V, MD, O'Malley, David M, MD, Kristeleit, Rebecca S, MD, Ma, Ling, MD, Bell-McGuinn, Katherine M, MD, Brenton, James D, Prof, Cragun, Janiel M, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, Prof, Harrell, Maria I, PhD, Mann, Elaina, MS, Kaufmann, Scott H, Prof, Floquet, Anne, MD, Leary, Alexandra, MD, Harding, Thomas C, PhD, Goble, Sandra, MS, Maloney, Lara, BA, Isaacson, Jeff, PhD, Allen, Andrew R, MD, Rolfe, Lindsey, MBChB, Yelensky, Roman, PhD, Raponi, Mitch, PhD, McNeish, Iain A, Prof

Volltext

EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression von Lheureux, Stephanie, Oaknin, Ana, Garg, Swati, Bruce, Jeffrey P., Madariaga, Ainhoa, Dhani, Neesha C., Bowering, Valerie, White, Justin, Accardi, Sarah, Tan, Qian, Braunstein, Marsela, Karakasis, Katherine, Cirlan, Iulia, Pedersen, Stephanie, Li, Tiantiam, Farinas-Madrid, Lorena, Lee, Yeh Chen, Liu, Zhihui (Amy), Pugh, Trevor J., Oza, Amit M.

Volltext

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas von Elkabets, Moshe, Pazarentzos, Evangelos, Juric, Dejan, Sheng, Qing, Pelossof, Raphael A., Brook, Samuel, Benzaken, Ana Oaknin, Rodon, Jordi, Morse, Natasha, Yan, Jenny Jiacheng, Liu, Manway, Das, Rita, Chen, Yan, Tam, Angela, Wang, Huiqin, Liang, Jinsheng, Gurski, Joseph M., Kerr, Darcy A., Rosell, Rafael, Teixidó, Cristina, Huang, Alan, Ghossein, Ronald A., Rosen, Neal, Bivona, Trever G., Scaltriti, Maurizio, Baselga, José

Volltext

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade von Romero, Octavio A., Vilarrubi, Andrea, Alburquerque-Bejar, Juan J., Gomez, Antonio, Andrades, Alvaro, Trastulli, Deborah, Pros, Eva, Setien, Fernando, Verdura, Sara, Farré, Lourdes, Martín-Tejera, Juan F., Llabata, Paula, Oaknin, Ana, Saigi, Maria, Piulats, Josep M., Matias-Guiu, Xavier, Medina, Pedro P., Vidal, August, Villanueva, Alberto, Sanchez-Cespedes, Montse

Volltext

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma von Lin, Kevin K, Harrell, Maria I, Oza, Amit M, Oaknin, Ana, Ray-Coquard, Isabelle, Tinker, Anna V, Helman, Elena, Radke, Marc R, Say, Carmen, Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D, Maloney, Lara, O'Malley, David M, Chambers, Setsuko K, Kaufmann, Scott H, Scott, Clare L, Konecny, Gottfried E, Coleman, Robert L, Sun, James X, Giordano, Heidi, Brenton, James D, Harding, Thomas C, McNeish, Iain A, Swisher, Elizabeth M

Volltext

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... von Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

Volltext

Advances in immunotherapy for cervical cancer von Grau-Bejar, Juan Francisco, Garcia-Duran, Carmen, Garcia-Illescas, David, Mirallas, Oriol, Oaknin, Ana

Volltext

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial von Audeh, M William, Dr, Carmichael, James, Prof, Penson, Richard T, MD, Friedlander, Michael, Prof, Powell, Bethan, Prof, Bell-McGuinn, Katherine M, PhD, Scott, Clare, MD, Weitzel, Jeffrey N, Prof, Oaknin, Ana, MD, Loman, Niklas, MD, Lu, Karen, Prof, Schmutzler, Rita K, Prof, Matulonis, Ursula, MD, Wickens, Mark, BSc, Tutt, Andrew, PhD

Volltext

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) von Swisher, Elizabeth M., Kwan, Tanya T., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L., Aghajanian, Carol, Konecny, Gottfried E., O’Malley, David M., Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-may, Wahner Hendrickson, Andrea E., Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S., Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H., Elvin, Julia A., Lin, Douglas I., Chambers, Setsuko K., Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L., Lin, Kevin K., McNeish, Iain A.

Volltext

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors von Poveda, Andres, Oaknin, Ana, Romero, Ignacio, Guerrero-Zotano, Angel, Fariñas-Madrid, Lorena, Rodriguez-Freixinos, Victor, Mallol, Pedro, Lopez-Reig, Raquel, Lopez-Guerrero, Jose Antonio

Volltext

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial von Monk, Bradley J, Prof, Poveda, Andrés, MD, Vergote, Ignace, MD, Raspagliesi, Francesco, MD, Fujiwara, Keiichi, MD, Bae, Duk-Soo, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, MD, Provencher, Diane M, MD, Karlan, Beth Y, MD, Lhommé, Catherine, MD, Richardson, Gary, MD, Rincón, Dolores Gallardo, MD, Coleman, Robert L, MD, Herzog, Thomas J, MD, Marth, Christian, PhD, Brize, Arija, MD, Fabbro, Michel, MD, Redondo, Andrés, MD, Bamias, Aristotelis, PhD, Tassoudji, Marjan, MS, Navale, Lynn, MS, Warner, Douglas J, MD, Oza, Amit M, MD

Volltext

Treatment of metastatic cervical cancer: Future directions involving targeted agents von Diaz-Padilla, Ivan, Monk, Bradley J, Mackay, Helen J, Oaknin, Ana

Volltext

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240) von Penson, Richard T, Prof, Huang, Helen Q, MS, Wenzel, Lari B, Prof, Monk, Bradley J, Prof, Stockman, Sharon, BA, Long, Harry J, Prof, Ramondetta, Lois M, MD, Landrum, Lisa M, PhD, Oaknin, Ana, MD, Reid, Thomas J A, MD, Leitao, Mario M, MD, Method, Michael, MD, Michael, Helen, Prof, Tewari, Krishnansu S, Prof

Volltext

Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer von MONK, Bradley J, MAS LOPEZ, Luis, ZARBA, Juan J, OAKNIN, Ana, TARPIN, Carole, TERMRUNGRUANGLERT, Wichai, ALBER, Jacquelyn A, JIE DING, STUTTS, Melissa W, PANDITE, Lini N

Volltext